NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Ok Flipper. I will taper off here. My last post was written same time as your prior. But it looks like the estimates of percentage of pseudoprogressors is so wide, 10% to 50% that it is very difficult to analyze much in that realm. Maybe that is not a super useful label.

Maybe more worthwhile to be analyzing around the more objective variable of Methylated MGMT. Whether that is native or tumor MGMT... whichever is appropriate. (Tumor is certainly appropriate but native is better if it correlates well enough because it is so convenient).

Perhaps they have submitted an AA request or some such for the Methylated MGMT patients. If that status is known for all patients from day 1, then they could send in the data for all patients, in and out of the trial, for consideration.